Treatment of Patients with Severe IgA Nephropathy (pishenyangxu Pattern)with Jianpibushentongluo Granules Plus Prednisone:A Randomized,controlled,and Double-Blind Multicentre Trial
CHEN Wan-jia,DENG Yue-yi,NI Zhao-hui,WANG Nian-song,WANG Yi,DENG Wei
DOI: https://doi.org/10.3877/cma.j.issn.2095-3216.2013.05.009
2013-01-01
Abstract:Objective To observe the safety and efficacy of Jianpibushentongluo granules plus prednisone in treating immunoglobulin A nephropathy (IgAN ) patients staging Lee Ⅲ and above (Pishenyangxu pattern).Methods A randomized,controlled,and double-blind multicentre clinical trial was conducted.From January 201 1 to February 201 2,a total of 1 20 IgAN patients (LeeⅢand above)from 4 hospitals in Shanghai were recruited.All of the patients presented with Pishenyangxu syndrome.The patients were randomly divided into two groups:test group (Jianpibushentongluo granules plus prednisone) and control group (placebo granules plus prednisone).According to the patient′s weight and renal function, the starting dose of oral prednisone was 40-60 mg/d for a total of 8 to 1 2 weeks;Thereafter,the oral prednisone dose was reduced by 5 mg every two weeks until the dose reached 30 mg/d,and then by 5 mg every month.Oral prednisone was stopped after 9 months of treatment.The Jianpibushentongluo granules were made from astragalus,sealwort,eucommia,prunella,fried caltrop,epimedium,poria,fried silkworm, and salvia,which were administered to patients for 48 weeks.Follow-up was performed at the 0,4,1 2,24, 36,and 48 week,monitoring estimated glomerular filtration rate (eGFR),symptoms of traditional Chinese medicine,serum creatinine,and 24-hour urinary protein excretion.Mixed model was used for analysis of repeated measuring data to compare efficacy difference between the two groups.P value less than 0.05 was considered statistically significant.Results 1 03 patients (test group 55 cases,control group 48 cases) completed the study.eGFR in both test and control group showed an increasing trend compared with baseline (t=4.84,2.37;P<0.05);eGFR level became higher at 24-week of treatment (P<0.05),and increased more from baseline in test group than in control group at 48-week of treatment (F=1 4.39,P<0.05).The syndrome scoring and 24 h urinary protein in both groups were lower than baseline (t=-1 2.1 ,-8.6;P<0.05).The syndrome scoring decreased more in test group than in control group (F=1 06.76,P<0.05), but the 24 h urinary protein decreased more in control group than in test group (F=46.24,P<0.05 ). Serum creatinine level decreased significantly than baseline in test group (t=-4.34,P<0.05),but not in control group (t =-1 .1 2,P>0.05 ).The total effective rate of syndromes treatment was higher in test group (83.33%,50/60)than in control group (63.33%,38/60)(χ2 =17.85,P<0.05).Adverse events occurred in 1 4 cases:test group 5 cases (5/60,8.3%),and control group 9 cases (9/60,1 5%) with no statistically significant difference between the two groups (χ2 =1 .294,P=0.255 ).Conclusion For IgAN patients staging Lee Ⅲ and above (Pishenyangxu pattern ),Jianpibushentongluo granules plus prednisone showed better efficacy and safety than prednisone alone in improving renal function and reducing clinical symptoms.